VESPR: Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women

• Sponsor: University of California, San Diego (Other)
• Overall Status: Completed
• CT.gov ID: NCT01958073
• Collaborator: American Urogynecologic Society (Other), NYU Langone Health (Other)
• Enrollment: 35
• Locations: 2
• Arms: 3
• Duration (Months): 50
• Patients Per Site: 17.5
• Patients Per Site Per Month: 0.3

Study Details

Study Description

Brief Summary

The investigators would like to know if the use of vaginally applied estrogen can prevent the problem of repeated urinary tract infections (UTI) in women who have gone through menopause. The investigators will use two forms of vaginal estrogen that are available by prescription (a ring and a cream) and compare their efficacy to that of a placebo (without any active ingredient). The investigators are going to look at if the vaginal estrogen can prevent UTIs altogether and also the number of UTIs each group experiences over a 6 month period. After 6 months, all subjects will receive vaginal estrogen and the women on the non-active treatment will be able to choose whether they would like to use either the estrogen ring or cream. The investigators will then be able to compare the number of UTIs on and off active vaginal estrogen treatment within those subjects who started on the placebo. The investigators are also going to look at quality of life before and during treatment using questionnaires and whether subjects stop using the treatments or do not use them as directed (compliance).

Condition or Disease	Intervention/Treatment	Phase
Recurrent Urinary Tract Infection	Drug: Conjugated Estrogen Vaginal Cream; Drug: Estradiol Ring; Drug: Placebo	Phase 4

Detailed Description

This was an investigator-initiated, multicenter, single-blind, randomized placebo-controlled trial of vaginal estrogen (delivered by estradiol ring or conjugated estrogen cream) compared to placebo cream. This study was conducted by the Divisions of Female Pelvic Medicine and Reconstructive Surgery at three academic institutions.

Potential participants were recruited from women receiving care for rUTIs in the clinics of each institution. Women were postmenopausal as defined by amenorrhea for >12 months, history of bilateral salpingoophrectomy, or in patients with prior hysterectomy defined as menopausal symptoms for >1 year or age >55. Participants had documented rUTI (three or more in one year or two in six months) by positive urine culture. Participants were excluded if they had undergone urologic surgery within three months of screening or planned surgery within one year of screening, had the diagnosis of painful bladder syndrome, history of UTI requiring the use of intravenous antibiotics or one oral antibiotic available for treatment based on allergies and resistance profiles, known etiology of infections (e.g. urologic stones, fistulas, fecal incontinence, catheterization or poorly controlled diabetes), urothelial cancer, or actively treated estrogen sensitive tumor. Participant enrollment was deferred in the setting of undiagnosed hematuria or vaginal bleeding, but enrollment could occur after negative workup for malignancy. Participants deferred enrollment if they used vaginal androgens, estrogens or progestins within six months or if they used medications or supplements known to prevent UTI (e.g. cranberry products, D mannose, prophylactic antibiotics, methenamine hippurate) within three months of enrollment, but could enroll after washout. Those with a remote history of estrogen-sensitive tumor required approval by her oncologist or primary care physician.

Participants were initially randomized to receive either vaginal estrogen (via estradiol ring or conjugated estrogen cream) or placebo cream in a 1:1:1 fashion and were told that there were placebo and vaginal estrogen arms, but were unaware that there was not a placebo ring. Participants were randomized to either conjugated estrogen cream at a strength of 0.625 mg/g dosed at 0.5g (0.312 mg) twice a week, estradiol ring containing 2mg of estradiol placed vaginally every three months by study personnel, or placebo cream which was an over-the-counter lubricant containing mineral oil, petrolatum, ceresin and paraffin dosed at 0.5g twice a week. If participants in any arm developed three UTI in the six-month treatment period, they were unblinded. If on placebo, they were provided active study drug or if they were in the vaginal estrogen arm, they were treated according to the provider's clinical practice and their outcomes recorded for the remainder of the study. The primary outcome of occurrence of UTI was assessed at six months or the end of study blinding, whichever occurred first. In order to improve recruitment and assess long-term compliance, satisfaction and efficacy, we offered open label use of estradiol ring or conjugated estrogen cream after unblinding until month 12 of the study.

Clean-catch urine cultures were collected when participants were symptomatic: fever (>38 degrees C), urgency, frequency, dysuria or suprapubic tenderness. Women were asked to have all urine labs done at the parent site as per standard clinical practice. The primary outcome of the study was the presence of a UTI in the randomized six months. We also assessed rates of UTI over the course of the 12-month study in all participants as-treated. Quality of life (QOL) questionnaires were administered at baseline, six months or unblinding, and 12 months. Questionnaires included the Pelvic Floor Distress Inventory (PFDI-20), Pelvic Floor Impact Questionnaire (PFIQ-7), Medical, Epidemiologic, and Social Aspects of Aging Questionnaire (MESA), Female Sexual Function Index (FSFI) and Patient Satisfaction Questionnaire (PSQ), Global Perception of Improvement (GPI) and Estimated Percent Improvement (EPI) rating scales. Baseline medical history and concomitant pelvic medicine diagnoses were also collected. Participants using a cream treatment were asked to keep medication diaries and return tubes for weighing at months three, six, nine and 12. Adherence was defined as presence of the estrogen ring or tube weights within 20% of expected at follow up visits. In addition, before unblinding, the participants were asked whether they believed they were on active treatment, placebo, or were unsure.

Study Design

• Study Type: Interventional
• Actual Enrollment: 35 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Participant)
• Primary Purpose: Prevention
• Official Title: Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized Clinical Trial
• Study Start Date: Oct 1, 2013
• Actual Primary Completion Date: Dec 1, 2017
• Actual Study Completion Date: Dec 1, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Conjugated Estrogen Vaginal Cream Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly	Drug: Conjugated Estrogen Vaginal Cream
Experimental: Estradiol Ring Estradiol Ring per vagina every 3 months	Drug: Estradiol Ring
Placebo Comparator: Placebo Per vagina	Drug: Placebo

Outcome Measures

Primary Outcome Measures

1. Occurrence of UTI During Randomization [6 months of the randomized period]

   The primary purpose of this study is to assess the efficacy of vaginal estrogen versus placebo at 6 months on the prevention of urinary tract infections (UTI) in postmenopausal women with history of recurrent UTI.

Secondary Outcome Measures

1. Rates of UTI in Both Randomization Period and Within Placebo When Changed to Open Label Estrogen [Assessed at 6 months for 'a'; assessed over 12 months for 'b']

   To assess overall rates of UTI over 6 months in postmenopausal women with history of recurrent UTI receiving vaginal estrogen (ring or cream). To compare rates of UTI between 6 and 12 months of those subjects initially randomized to placebo.

2. Quality of Life Questionnaire: Female Sexual Function Index [6 months of the randomized period]

   To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Female Sexual Function Index. Scale range 2-95. Lower score corresponds to worse functioning.

3. Compliance During Randomization [6 months of the randomized period]

   To assess compliance with vaginal estrogen (ring or cream) treatment at 6 months in postmenopausal women with history of recurrent UTI.

4. Occurrence of UTI in Those Compliant With Treatment During Randomization [6 months of the randomized period]

   To assess efficacy of vaginal estrogen at 6 months in those compliant with treatment.

5. Quality of Life Questionnaire: MESA I [6 months of the randomized period]

   To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Medical, Epidemiologic, and Social Aspects of Aging Questionnaire (MESA) urinary incontinence questionnaire: stress urinary incontinence subscale. Subscale range 0-27. A higher score indicated more frequent symptoms.

6. Quality of Life Questionnaire: MESA II [6 months of the randomized period]

   To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Medical, Epidemiologic, and Social Aspects of Aging Questionnaire (MESA) urinary incontinence questionnaire: urgency urinary incontinence subscale. Subscale range 0-18. High score indicates more frequent symptoms.

7. Quality of Life Questionnaire: Pelvic Floor Disability Index [6 months of the randomized period]

   To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Pelvic Floor Disability Index. Scale range 0-100. Higher score corresponds to increased bother.

8. Quality of Life Questionnaire: Pelvic Floor Impact Questionnaire [6 months of the randomized period]

   To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Pelvic Floor Impact Questionnaire. Scale range 0-300. Higher score corresponds to increasing bother.

9. Quality of Life Questionnaire: Estimated Percentage of Improvement [6 months of the randomized period]

   To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Estimated Percentage of Improvement. Scale range 0-100. Higher score corresponds to more improvement.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 100 Years
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Postmenopausal status as defined by amenorrhea for >12 months, OR history of bilateral salpingoophrectomy, OR if the patient has had a hysterectomy defined by menopausal symptoms for >1 year OR age >55

2. Documented recurrent UTIs (3 or more in the last year or 2 or more in the last 6 months)- one UTI must be documented by culture, others may be documented by urinalysis

3. Ability to provide informed consent

Exclusion Criteria:

1. Use of any investigational drug or device within thirty days of screening

2. Urologic surgery within the past 3 months of screening or plan for surgery within one year of screening

3. Diagnosis of Interstitial Cystitis/painful bladder syndrome

4. History of urinary tract infections which require the use of IV antibiotics or where only one oral antibiotic is available for treatment, or where the risk of treatment with vaginal estrogen only is deemed unacceptable by the principle investigator secondary to the severity of prior urinary tract infections

5. Known etiology of infection such as, but not limited to: kidney or bladder stones, enterovaginal/vesical fistula, fecal incontinence, intermittent catheterization, indwelling catheter, poorly controlled diabetes

6. Urothelial cancer

7. Actively treated estrogen sensitive tumor (breast or endometrial cancer)

8. Undiagnosed vaginal bleeding

9. Inability to use a vaginal ring (secondary to advanced prolapse or shortened vaginal length)

10. Any medical reason the investigator deems incompatible with treatment with vaginal estrogen

11. Prolapse requiring pessary use

Deferral Criteria

1. Undiagnosed hematuria - may enroll after malignancy is ruled out

2. Use of a progestin containing intrauterine device or use of any vaginal androgens, estrogens or progestins within 3 months of enrollment - may enroll after wash out

3. Use of drugs/supplements known to prevent UTIs (ie cranberry products, prophylactic antibiotics, methenamine hippurate) 1 month prior to enrollment - may enroll after wash out if still meets inclusion criteria.

4. History of estrogen sensitive tumor (breast or endometrial cancer) - requires approval by the subject's primary oncologist or primary care physician

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of California, San Diego	La Jolla	California	United States	92037
2	New York University Langone Medical Center	New York	New York	United States	10016

Sponsors and Collaborators

• University of California, San Diego
• American Urogynecologic Society
• NYU Langone Health

Investigators

None specified.

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Feb 21, 2017

More Information

Publications

None provided.

• Responsible Party: Kimberly Ferrante, MD, Female Pelvic Medicine and Reconstructive Surgery Attending, NYU Langone Health
• ClinicalTrials.gov Identifier: NCT01958073
• Other Study ID Numbers: 130403
• First Posted: Oct 8, 2013
• Last Update Posted: Sep 21, 2020
• Last Verified: Aug 1, 2020

• Keywords provided by Kimberly Ferrante, MD, Female Pelvic Medicine and Reconstructive Surgery Attending, NYU Langone Health: Recurrent Urinary Tract Infection; Postmenopausal; Vaginal Estrogen
• Additional relevant MeSH terms: Infections; Communicable Diseases; Urinary Tract Infections; Recurrence; Estradiol; Estrogens; Estrogens, Conjugated (USP)

Study Results

Participant Flow

Pre-assignment Detail	At the start of the study we began with the intent of 3 groups for analysis, separating the two forms of vaginal estrogen into separate groups and comparing them to a placebo group. Due to difficulties with recruitment, our protocol was amended so that the two vaginal estrogen groups were combined to one vaginal estrogen group compared to placebo.

Arm/Group Title	Conjugated Estrogen Vaginal Cream	Estradiol Ring	Placebo	Vaginal Cream Open Label	Estradiol Ring Open Label
Arm/Group Description	Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly Conjugated Estrogen Vaginal Cream	Estradiol Ring per vagina every 3 months Estradiol Ring	Per vagina 0.5g 2 times weekly Placebo	Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly Conjugated Estrogen Vaginal Cream	Estradiol Ring per vagina every 3 months Estradiol Ring
Period Title: Randomized Period
STARTED	9	9	17	0	0
COMPLETED	7	8	11	0	0
NOT COMPLETED	2	1	6	0	0
Period Title: Randomized Period
STARTED	0	0	0	5	17
COMPLETED	0	0	0	5	17
NOT COMPLETED	0	0	0	0	0

Baseline Characteristics

Arm/Group Title	Placebo	Vaginal Estrogen	Total
Arm/Group Description	Per vagina 0.5g 2 times weekly Placebo	Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly OR Estradiol Ring per vagina every 3 months	Total of all reporting groups
Overall Participants	17	18	35
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	67.5 (10.47)	72.8 (8.4)	70.15 (9.72)
Sex: Female, Male (Count of Participants)
Female	17 100%	18 100%	35 100%
Male	0 0%	0 0%	0 0%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	2 11.8%	2 11.1%	4 11.4%
Not Hispanic or Latino	15 88.2%	16 88.9%	31 88.6%
Unknown or Not Reported	0 0%	0 0%	0 0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	1 5.6%	1 2.9%
Asian	0 0%	1 5.6%	1 2.9%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%
Black or African American	1 5.9%	0 0%	1 2.9%
White	16 94.1%	16 88.9%	32 91.4%
More than one race	0 0%	0 0%	0 0%
Unknown or Not Reported	0 0%	0 0%	0 0%
Region of Enrollment (participants) [Number]
United States	17 100%	18 100%	34 97.1%
BMI (kg/m^2) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [kg/m^2]	28.41 (7.09)	30.33 (9.21)	29.37 (8.15)
Number of UTIs in prior 12 months (Count of Participants)
2	6 35.3%	7 38.9%	13 37.1%
3	7 41.2%	9 50%	16 45.7%
4	2 11.8%	1 5.6%	3 8.6%
5	1 5.9%	1 5.6%	2 5.7%
6	1 5.9%	0 0%	1 2.9%
Smoking (Count of Participants)
Current	1 5.9%	1 5.6%	2 5.7%
Former	8 47.1%	7 38.9%	15 42.9%
Never	8 47.1%	10 55.6%	18 51.4%
Marital Status (Count of Participants)
Single	0 0%	3 16.7%	3 8.6%
Married	6 35.3%	5 27.8%	11 31.4%
Divorced/Separated	7 41.2%	2 11.1%	9 25.7%
Widowed	3 17.6%	8 44.4%	11 31.4%
Other	1 5.9%	0 0%	1 2.9%
Education (Count of Participants)
Less than High School	0 0%	1 5.6%	1 2.9%
High School/GED	5 29.4%	4 22.2%	9 25.7%
Associates Degree	3 17.6%	4 22.2%	7 20%
4 year college	5 29.4%	5 27.8%	10 28.6%
Graduate School	4 23.5%	4 22.2%	8 22.9%
Caffeine use (Count of Participants)
Count of Participants [Participants]	14 82.4%	14 77.8%	28 80%
Prior Pelvic Surgery (Count of Participants)
Count of Participants [Participants]	9 52.9%	13 72.2%	22 62.9%
Prior Vaginal Estrogen (Count of Participants)
Count of Participants [Participants]	4 23.5%	1 5.6%	5 14.3%
Hormone Replacement Therapy (Count of Participants)
Never	10 58.8%	6 33.3%	16 45.7%
Past	5 29.4%	10 55.6%	15 42.9%
Current	2 11.8%	1 5.6%	3 8.6%
Diabetes (Count of Participants)
Count of Participants [Participants]	4 23.5%	3 16.7%	7 20%

Outcome Measures

1. Primary Outcome

Title	Occurrence of UTI During Randomization
Description	The primary purpose of this study is to assess the efficacy of vaginal estrogen versus placebo at 6 months on the prevention of urinary tract infections (UTI) in postmenopausal women with history of recurrent UTI.
Time Frame	6 months of the randomized period

Outcome Measure Data

Analysis Population Description

As treated. Vaginal estrogen groups were combined due to a protocol amendment.

Arm/Group Title	Vaginal Estrogen	Placebo
Arm/Group Description	Conjugated Estrogen Vaginal Cream OR Estradiol Ring	Per vagina Placebo
Measure Participants	15	11
Count of Participants [Participants]	8 47.1%	10 55.6%

2. Secondary Outcome

Title	Rates of UTI in Both Randomization Period and Within Placebo When Changed to Open Label Estrogen
Description	To assess overall rates of UTI over 6 months in postmenopausal women with history of recurrent UTI receiving vaginal estrogen (ring or cream). To compare rates of UTI between 6 and 12 months of those subjects initially randomized to placebo.
Time Frame	Assessed at 6 months for 'a'; assessed over 12 months for 'b'

Outcome Measure Data

Analysis Population Description

As treated. Vaginal estrogen groups were combined due to a protocol amendment.

Arm/Group Title	Placebo During Randomization	Vaginal Estrogen	Initial Placebo to Open Label Vaginal Estrogen
Arm/Group Description	Per vagina 0.5g 2 times weekly Placebo	Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly OR Estradiol Ring per vagina every 3 months	Those participants initially randomized to placebo, during the period when they went on open label vaginal estrogen.
Measure Participants	11	15	10
No UTI	1 5.9%	8 44.4%	7 20%
1 UTI	7 41.2%	3 16.7%	2 5.7%
2 UTI	2 11.8%	4 22.2%	1 2.9%
3 UTI	1 5.9%	0 0%	0 0%

3. Secondary Outcome

Title	Quality of Life Questionnaire: Female Sexual Function Index
Description	To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Female Sexual Function Index. Scale range 2-95. Lower score corresponds to worse functioning.
Time Frame	6 months of the randomized period

Outcome Measure Data

Analysis Population Description

As treated. Vaginal estrogen groups were combined due to a protocol amendment.

Arm/Group Title	Placebo	Vaginal Estrogen
Arm/Group Description	Per vagina 0.5g 2 times weekly Placebo	Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly OR Estradiol Ring per vagina every 3 months
Measure Participants	11	15
Mean (Standard Deviation) [score on a scale]	43.45 (27.83)	30.64 (29.38)

4. Secondary Outcome

Title	Compliance During Randomization
Description	To assess compliance with vaginal estrogen (ring or cream) treatment at 6 months in postmenopausal women with history of recurrent UTI.
Time Frame	6 months of the randomized period

Outcome Measure Data

Analysis Population Description

as treated, we did not collect data from the placebo group; although vaginal estrogen groups were combined in a protocol amendment for the primary outcome, they were not combined for this secondary outcome looking at compliance

Arm/Group Title	Conjugated Estrogen Vaginal Cream	Estradiol Ring
Arm/Group Description	Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly Conjugated Estrogen Vaginal Cream	Estradiol Ring per vagina every 3 months Estradiol Ring
Measure Participants	7	8
Count of Participants [Participants]	4 23.5%	8 44.4%

5. Secondary Outcome

Title	Occurrence of UTI in Those Compliant With Treatment During Randomization
Description	To assess efficacy of vaginal estrogen at 6 months in those compliant with treatment.
Time Frame	6 months of the randomized period

Outcome Measure Data

Analysis Population Description

as treated; although vaginal estrogen groups were combined in a protocol amendment for the primary outcome, they were not combined for this secondary outcome looking at compliance. Compliance was not assessed in placebo which was used as a comparator group for this outcome.

Arm/Group Title	Conjugated Estrogen Vaginal Cream	Estradiol Ring	Placebo
Arm/Group Description	Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly Conjugated Estrogen Vaginal Cream	Estradiol Ring per vagina every 3 months Estradiol Ring	Per vagina Placebo
Measure Participants	4	8	11
Count of Participants [Participants]	3 17.6%	5 27.8%	10 28.6%

6. Secondary Outcome

Title	Quality of Life Questionnaire: MESA I
Description	To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Medical, Epidemiologic, and Social Aspects of Aging Questionnaire (MESA) urinary incontinence questionnaire: stress urinary incontinence subscale. Subscale range 0-27. A higher score indicated more frequent symptoms.
Time Frame	6 months of the randomized period

Outcome Measure Data

Analysis Population Description

As treated. Vaginal estrogen groups were combined due to a protocol amendment.

Arm/Group Title	Placebo	Vaginal Estrogen
Arm/Group Description	Per vagina 0.5g 2 times weekly Placebo	Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly OR Estradiol Ring per vagina every 3 months
Measure Participants	11	15
Mean (Standard Deviation) [score on a scale]	7.00 (7.27)	9.86 (6.93)

7. Secondary Outcome

Title	Quality of Life Questionnaire: MESA II
Description	To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Medical, Epidemiologic, and Social Aspects of Aging Questionnaire (MESA) urinary incontinence questionnaire: urgency urinary incontinence subscale. Subscale range 0-18. High score indicates more frequent symptoms.
Time Frame	6 months of the randomized period

Outcome Measure Data

Analysis Population Description

As treated. Vaginal estrogen groups were combined due to a protocol amendment.

Arm/Group Title	Placebo	Vaginal Estrogen
Arm/Group Description	Per vagina 0.5g 2 times weekly Placebo	Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly OR Estradiol Ring per vagina every 3 months
Measure Participants	11	15
Mean (Standard Deviation) [score on a scale]	4.82 (5.76)	4.79 (3.21)

8. Secondary Outcome

Title	Quality of Life Questionnaire: Pelvic Floor Disability Index
Description	To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Pelvic Floor Disability Index. Scale range 0-100. Higher score corresponds to increased bother.
Time Frame	6 months of the randomized period

Outcome Measure Data

Analysis Population Description

As treated. Vaginal estrogen groups were combined due to a protocol amendment.

Arm/Group Title	Placebo	Vaginal Estrogen
Arm/Group Description	Per vagina 0.5g 2 times weekly Placebo	Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly OR Estradiol Ring per vagina every 3 months
Measure Participants	11	15
Mean (Standard Deviation) [score on a scale]	65.88 (56.29)	55.53 (31.76)

9. Secondary Outcome

Title	Quality of Life Questionnaire: Pelvic Floor Impact Questionnaire
Description	To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Pelvic Floor Impact Questionnaire. Scale range 0-300. Higher score corresponds to increasing bother.
Time Frame	6 months of the randomized period

Outcome Measure Data

Analysis Population Description

As treated. Vaginal estrogen groups were combined due to a protocol amendment.

Arm/Group Title	Placebo	Vaginal Estrogen
Arm/Group Description	Per vagina 0.5g 2 times weekly Placebo	Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly OR Estradiol Ring per vagina every 3 months
Measure Participants	11	15
Mean (Standard Deviation) [score on a scale]	22.08 (44.01)	9.86 (14.88)

10. Secondary Outcome

Title	Quality of Life Questionnaire: Estimated Percentage of Improvement
Description	To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Estimated Percentage of Improvement. Scale range 0-100. Higher score corresponds to more improvement.
Time Frame	6 months of the randomized period

Outcome Measure Data

Analysis Population Description

As treated. Vaginal estrogen groups were combined due to a protocol amendment.

Arm/Group Title	Placebo	Vaginal Estrogen
Arm/Group Description	Per vagina 0.5g 2 times weekly Placebo	Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly OR Estradiol Ring per vagina every 3 months
Measure Participants	11	15
Mean (Standard Deviation) [percentage of improvement]	33.00 (35.48)	74.64 (25.83)

Adverse Events

Time Frame	Adverse events were collected up to 1 year after start of study participation
Arm/Group Title	Placebo		Vaginal Estrogen Cream Randomization		Vaginal Estrogen Ring Randomization		Vaginal Estrogen Cream Open Label		Vaginal Estrogen Ring Open Label
Arm/Group Description	Per vagina 0.5g 2 times weekly Placebo		Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly		Estradiol Ring per vagina every 3 months		Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly		Estradiol Ring per vagina every 3 months
All Cause Mortality
	Placebo		Vaginal Estrogen Cream Randomization		Vaginal Estrogen Ring Randomization		Vaginal Estrogen Cream Open Label		Vaginal Estrogen Ring Open Label
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/17 (0%)		0/9 (0%)		0/9 (0%)		0/5 (0%)		0/17 (0%)
Serious Adverse Events
	Placebo		Vaginal Estrogen Cream Randomization		Vaginal Estrogen Ring Randomization		Vaginal Estrogen Cream Open Label		Vaginal Estrogen Ring Open Label
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/17 (0%)		0/9 (0%)		0/9 (0%)		0/5 (0%)		0/17 (0%)
Other (Not Including Serious) Adverse Events
	Placebo		Vaginal Estrogen Cream Randomization		Vaginal Estrogen Ring Randomization		Vaginal Estrogen Cream Open Label		Vaginal Estrogen Ring Open Label
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/17 (0%)		0/9 (0%)		0/9 (0%)		0/5 (0%)		0/17 (0%)

Limitations/Caveats

Difficult recruitment requiring several modifications to the study design, single-blind nature of the trial, underpowered for secondary outcomes.

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.